| Name | Title | Contact Details |
|---|---|---|
Angad Singh |
Chief Technology Officer | Profile |
The Cerulean team is committed to improving treatment for people living with cancer. We apply our Dynamic Tumor Targeting Platform to create a portfolio of NDCs designed to selectively attack tumor cells, reduce toxicity by sparing the body’s normal cells, and enable therapeutic combinations. Our first platform-generated candidate, CRLX101, is in multiple clinical trials in combination with other cancer treatments, all of which aim to unlock the power of combination therapy. Our second platform-generated candidate, CRLX301, is in a Phase 1/2a clinical trial.
Zygote is a Lindon, UT-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Astra Zeneca Neuroscience is a Cambridge, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Bio Essence Corp is a Richmond, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Gennao Bio is a privately held genetic medicines company developing first-in-class targeted nucleic acid therapeutics utilizing a proprietary gene monoclonal antibody (GMAB) platform technology.